CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
reMARK-AML is focused on improving risk assessment in acute myeloid leukemia by identifying new biomarkers at the single-cell level. This project aims to develop diagnostic tools that can better predict patient outcomes and guide treatment strategies for this aggressive cancer.
Acute myeloid leukemia (AML) is one of the most aggressive, clinically and biologically heterogenenous, hematological alignancies.
The different genetics classify disease entities, and define the prognostic risk category to which AML patients are assigned and the treatment choices.There is one entity, the AML with nucleophosmin (NPM1) gene mutations, that accounts for onethird of all adult AML (the most frequent) and where another gene mutation - the Fms-like tyrosine kinase 3 (FLT3)-internal ta…
UNIVERSITA DEGLI STUDI DI PERUGIA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
